Suicidal behavior and ideation section removed from the Saxenda label

Novo Nordisk's Saxenda (liraglutide) 3 mg injection, approved for chronic weight management, no longer carries a "Suicidal Behavior and Ideation" warning in its US prescribing information. The label's Recent Major Changes table lists Warnings and Precautions subsection 5.9, Suicidal Behavior and Ideation, as "(Removed) 02/2026," and the document is marked Revised: 02/2026 ^[1].

The change is not limited to the brand. A generic liraglutide 3 mg injection labeled by Teva Pharmaceuticals and posted on DailyMed was updated February 27, 2026, with the identical entry: "Suicidal Behavior and Ideation (5.9)……(Removed) 2/2026" ^[2]. Generic labels generally mirror the brand, so the update moved across the liraglutide weight-management products together.

What the label says now

The number 5.9 has been reassigned. In the current Saxenda and generic liraglutide labels, subsection 5.9 is "Pulmonary Aspiration During General Anesthesia or Deep Sedation," which notes that aspiration has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures and instructs patients to tell health care providers about planned surgeries or procedures ^[1][2].

The remaining Warnings and Precautions are unchanged: the boxed warning about thyroid C-cell tumors in rodents and the contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN 2; acute pancreatitis; acute gallbladder disease; hypoglycemia, including in pediatric patients without type 2 diabetes; heart rate increase; acute kidney injury from volume depletion; severe gastrointestinal reactions, with liraglutide not recommended in severe gastroparesis; and hypersensitivity reactions ^[1][2].

This is the fourth listed label change in under a year. The Indications and Usage section was revised in May 2025, a Patient Selection subsection (2.1) and a pregnancy contraindication were removed in May 2025, and the Severe Gastrointestinal Adverse Reactions warning was updated in October 2025 ^[1][2].

The sources do not include an FDA statement, review memo or press release explaining the reasoning behind the February 2026 removal, so the specific evidence the agency relied on is not yet known from these documents. The sources also do not say whether labels for other GLP-1 medicines changed at the same time.

What the safety data show

A pharmacovigilance analysis published in 2026 in Frontiers in Pharmacology looked at suicide- and self-injury-related reports for liraglutide, semaglutide and tirzepatide in EudraVigilance, the European reporting database, covering January 1, 2021 through December 31, 2025 ^[3].

The authors included 42,941 eligible reports. Most involved semaglutide, followed by tirzepatide and liraglutide. Gastrointestinal disorders were the most commonly reported adverse events. Suicide and self-injury events made up a small share of the total: 37 cases for liraglutide, 141 for semaglutide and 47 for tirzepatide ^[3].

Compared with tirzepatide, reporting of these events was more frequent for liraglutide (reporting odds ratio 2.54, 95% confidence interval 1.60–4.01) and semaglutide (ROR 2.69, 95% CI 1.91–3.83) ^[3]. The authors stress that these numbers are a disproportionality comparison, not evidence of cause: "These findings do not establish a causal link between GLP-1 and GLP-1/GIP RAs and suicide or self-injury events," and the results "do not contradict regulatory conclusions" ^[3]. They also note that "European and United States regulatory agencies have not confirmed a causal relationship between these drugs and suicidality," while calling for continued monitoring as weight-management use grows ^[3].

Why it matters for patients

For people taking Saxenda or generic liraglutide 3 mg, the practical effect is what appears in the printed information. A prescriber or pharmacist reviewing the current label will no longer find a dedicated warning about suicidal behavior and ideation, and the Medication Guide accompanies a label that has dropped that subsection ^[1][2].

That is a documentation change, not a finding that the question is closed. The published analysis still counted suicide- and self-injury-related reports for all three molecules and recommended continued pharmacovigilance ^[3]. Spontaneous reporting systems like EudraVigilance cannot show how often an event happens or whether a drug caused it, a limitation the authors flag directly ^[3].

The other safety sections people often ask about, including pancreatitis, gallbladder disease, severe GI reactions and the anesthesia aspiration warning, remain in place ^[1][2]. Patients and prescribers can report suspected adverse reactions to Novo Nordisk at 1-844-363-4448, to Teva at 1-888-838-2872, or to FDA at 1-800-FDA-1088 ^[1][2].